Purpose: The dimeric transmembrane integrin, α v β 3 , is a well-investigated target by different imaging modalities through suitably labeled arginine-glycine-aspartic acid (RGD) containing peptides. In this study, we labeled four cyclic RGD peptides with or without PEG functional groups: c(RGDfK) (denoted as FK), PEG 3 -c(RGDfK) ( from the tumor region of peptide tracers prepared for this study and the increased uptake in the bone of transchelated 89 Zr with time (2.0±0.36%ID/g, 24 h post-injection).
Introduction
A ngiogenesis (new vessel formation) is a crucial process for tumor growth and metastasis [1] [2] [3] [4] [5] [6] [7] [8] . In order to induce angiogenesis, angiogenic factors are released by the tumor to activate endothelial cells in established blood vessels and induce endothelial proliferation and migration.
Integrins are a family of heterodimeric transmembrane glycoproteins which play an essential role in the regulation of cellular adhesion, migration, proliferation, survival, signal transduction, and differentiation [7] [8] [9] . One member of this receptors class is the dimeric transmembrane integrin, α v β 3 , which is expressed at low levels on epithelial cells and mature endothelial cells. Upon activation of endothelial cells, α v β 3 is upregulated on the cell membrane. In addition, several tumors including osteosarcomas, neuroblastomas, glioblastomas, melanomas, lung carcinomas, and breast cancers were shown to express this integrin [1, [10] [11] [12] [13] . Hence, integrin α v β 3 expression can be targeted for imaging tumor growth, invasion, and metastasis, and for treatment of the rapidly growing and metastatic tumors [1, [14] [15] [16] .
Integrin α v β 3 interacts with extracellular matrix proteins (e.g., vitronectin, tenascin, fibronectin, and collagen) through their exposed arginine-glycine-aspartic acid (RGD) amino acid moieties and it regulates the migration of endothelial cells through the extracellular matrix during vessel formation [17] [18] [19] [20] . A number of cyclic RGD peptide moieties have been investigated as imaging probes for monitoring integrin α v β 3 expression level in tumors, using different molecular imaging modalities such as positron emission tomography (PET), single photon emission computed tomography, optical imaging, magnetic resonance imaging, and ultrasound [6, 8, 14, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . For radionuclide imaging of integrin α v β 3 expression in vivo, tumor-targeting efficacy and in vivo kinetic profiles are highly related to the receptor-binding affinity and specificity, hydrophilicity, molecular size, and overall molecular charge of the resulting radiotracers [13] .
Here we report on the evaluation of four different cyclic RGD peptides ( Fig. 1 ) labeled with a relatively long-lived PET isotope, zirconuim-89 ( 89 Zr, t 1/2 =78.4 h, β + =22.7%, maximum β + energy=0.897 MeV, electron capture=76.6%), to visualize integrin α v β 3 expression in vivo.
The long half-life of 89 Zr along with its other physical properties make it a favorable isotope for labeling antibodies which have slow pharmacokinetics in vivo, and it allows tracking and quantification for longer periods. We hypothesized that labeling RGD peptides with 89 Zr may give high-resolution PET images at delayed time points. In this study, we evaluated the differences between the four labeled RGD peptides in terms of binding affinity and tumor-targeting efficacy in vivo. Determining tumor integrin α v β 3 expression by using 89 Zr-RGD peptides and PET scan could be useful in predicting tumor behavior and responses to antiangiogenic therapies, including therapies targeting integrin α v β 3 . This could lead to more effective "personalized" cancer treatments.
Materials and Methods

General
Desferrioxamine-p-SCN (Df) was purchased from Macrocyclics (Dallas, TX, USA). All other solvents and chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA Synthesis of NH 2 -Mini-PEG-c(RGDfk) (PEG 3 -c (RGDfk)) PEG 3 -c(RGDfk) (denoted as FK-PEG 3 ) was prepared according to a known procedure [34] . Briefly, to a solution of Boc-11-amino-3,6,9-trioxaundecanoic acid (Boc-NH-mini-PEG-COOH, 0.51 mg, 1.66 mmol) and 0.26 mL N,N-diisopropylethylamine in acetonitrile (ACN) was added O-(N-succinimidyl)-1,1,3,3-tetramethyl-uronium tetrafluoroborate (0.34 mg, 1.15 mmol). The reaction mixture was stirred at room temperature for 0.5 h and then added to c(RGDfk) (28 mg, 46 μmol) in N,N′-dimethylformamide. The reaction was stirred at room temperature for another 2 h and the desired product, Boc-NH-mini-PEG-c(RGDfk), was isolated by semipreparative highperformance liquid chromatography (HPLC). The collected fractions were combined and lyophilized to give a fluffy white powder (60% yield). The Boc group was readily removed by treating Boc-NHmini-PEG-c(RGDfk) with anhydrous trifluoroacetic acid (TFA) for 5 min at room temperature. The crude product was purified on a reversed-phase HPLC system using a Higgins preparative C 18 column (5 μm, 20×250 mm). The flow was set at 12 mL/min using a gradient system, starting from 95% of solvent A (0.1% TFA in water) and 5% of solvent B (0.1% TFA in ACN) and increasing to 35% solvent A and 65% solvent B at 35 min. The desired peptide had a retention time of 13.8 min. The collected fractions were combined and lyophilized to afford FK-PEG 3 as a white powder.
Conjugation of the Peptides with Df
The conjugation procedure of Df with RGD peptide moieties was conducted by dissolving the peptide (1-2 mg) in 0.2-0.3 mL dimethylsulfoxide (DMSO). Then, 1.2 eq. of Df in 0.1 mL of DMSO were added, followed by addition of 5 eq. of diisopropylethylamine. The reaction was mixed at room temperature for 4-5 h. Purification of the conjugated peptides was conducted on a reversed-phase HPLC system using a Higgins preparative C 18 column (5 μm, 20×250 mm). The flow was set at 12 mL/min using a gradient system, starting from 95% of solvent A (0.1% TFA in water) and 5% of solvent B (0.1% TFA in ACN) and increasing to 35% solvent A and 65% solvent B at 35 min. The retention times were as follows: Df-FK, 24.8 min; Df-FK-PEG 3 
Mass Spectrometry Analysis
LC/MS analysis employed a Waters LC-MS system (Waters Corporation) that included an Acquity UPLC system coupled to the Waters Q-Tof Premier high-resolution mass spectrometer. An Acquity BEH Shield RP18 column (150×2.1 mm) was employed for chromatography. Elution was achieved with a binary mixture of two components. Solution A was composed of 2 mM ammonium formate, 0.1% formic acid, and 5% ACN; solution B was composed of 2 mM ammonium formate and 0.1% formic acid in ACN. The elution profile, at 0.35 mL/min, had the following components: initial condition at 100% (v:v) A and 0% B; gradient 0-40% B over 5 min; isocratic elution at 40% B for an additional 5 min; 40-80% B over 2 min; and re-equilibrated with A for an additional 3 min. 
Zr Production
Pressed pellets of yttrium metal mesh (200 mg, 4 N purity; American Elements) were irradiated with a proton beam of 15 MeV and a current of 20 μA for 2-4 h on a GE PETtrace cyclotron. The production rate was 1.17 ±0.05 mCi/μA h (n=10). 89 Zr was separated as 89 Zr-oxalate from the irradiated yttrium mesh using the method of Holland and co-workers [35] . Briefly, to a mini-vial charged with the irradiated metal was carefully added 6 N HCl (4×0.5 mL) and ultra-pure 10 M H 2 O 2 (100 μL, Fluka). The resulting solution was warmed to 80°C before dilution with 18 mΩ H 2 O (5 mL) and loading onto a pre-washed column of hydroxamate resin (200 mg). The resin was washed with 2 N HCl (4×2.5 mL) followed by 18 mΩ H 2 O (4×2.5 mL). 89 Zr was eluted with 1.0 M oxalic acid (4×0.5 mL and 2× 1.0 mL) in greater than 96% radiochemical yield. The 89 Zroxalate yield for a 2-h irradiation was 44.2±2.1 mCi (n=6) at end of bombardment.
89
Zr Radiolabeling 89 Zr labeling was done similarly to the known procedure [36] . Briefly, 220 μL of 89 Zr-oxalate (1.6-2.2 mCi, 59-81 MBq) was transferred into a glass tube, followed by addition of 100 μL 2 M Na 2 CO 3 . The reaction was incubated for 2-3 min at room temperature. Thereafter, 0.5 mL of 0.5 M HEPES buffer (pH = 7.2) was added to the reaction vial. The pH of the reaction vial was measured to be approximately 7-7. 
MDA-MB-435 Cell Culture
MDA-MB-435 cell line was purchased from American Type Culture Collection and grown in Leibovitz's L-15 medium (Gibco) supplemented with 10% (v/v) fetal bovine serum at 37°C under an atmosphere containing 5% CO 2 .
Integrin α v β 3 Receptor Competition Cell Binding Assay
Competition cell binding assay was done using integrin α v β 3 -specific radioligand, 125 I-echistatin. MDA-MB-435 cells were grew up to 80% confluence and then scraped off and resuspended with binding buffer [ 
Tumor Xenograft Model
Athymic nude mice were purchased from Harlan (Frederick, MD, USA) and housed under pathogen-free conditions. All animal studies were conducted in accordance with the principles and procedures outlined in the National Institutes of Health (NIH) Guide for the Care and Use of Animals, and under protocols approved by the NIH Clinical Center Animal Care and Use Committee. The MDA-MB-435 tumor model was generated by orthotopic injection of 5×10 6 cells in the left mammary fat pad of each female athymic nude mouse.
PET Studies
Tumor-bearing mice were anesthetized using isoflurane/O 2 (1.5-2% v/v) and injected with 100 μCi (3. 4 were co-injected with 300 μg of unlabeled c (RGDfk). Each group contained four to five mice. The images were reconstructed by a three-dimensional ordered subsets expectation maximum (3D-OSEM) algorithm, and no correction was applied for attenuation or scatter. Image analysis was done using ASI Pro VM TM software. The percentage of injected dose per gram (%ID/g) for the various tissues was determined by drawing regions of interest (ROIs) surrounding the entire organ on the coronal images. The radioactivity contained in the ROI divided by the dose administered to the animal gave the %ID and the volume of the ROI was converted to mass assuming a density of 1 for all tissues.
Biodistribution
Each mouse was intravenously injected 100 μCi (3. At different time points post-injection, blood was drawn from the heart, under anesthesia, and the mice were then sacrificed. Liver, muscle, kidneys, intestine, bone, spleen, pancreas, lung, stomach, heart, and tumor were removed. The organs were wet weighed and assayed for radioactivity using a gamma counter. For blocking experiment, 300 μg of unlabeled c (RGDfk) were co-injected with the appropriately labeled peptide. Each group contained four to five mice.
Statistical Analysis
Results were expressed as mean and SD. Two-tailed paired and unpaired Student's t tests were used to determine differences within groups and between groups, respectively. P values G0.05 were considered statistically significant.
Results
Chemistry and Radiochemistry
Conjugation of Df with RGD peptides was done in DMSO in the presence of diisopropylethylamine at room temperature, to give the conjugated peptides in high chemical yield of 80-90%, after HPLC purification. After lyophilization, the conjugated Df-RGD peptides were obtained as fluffy white powders. The Df-RGD conjugates were not completely soluble in water; therefore, a concentrated stock solution (10 mg/mL) of each conjugate was prepared in DMSO. For the radiolabeling, only 10-20 μg of each Df-RGD peptide was diluted with 0.5 M HEPES buffer for each reaction.
89 Zr complexation into the desired Df-RGD peptides was very efficient. Following incubation at room temperature for 20 min, almost no free 89 Zr was detected by radio-TLC. The overall radiochemical yield for all peptides was 89±4% (not decay-corrected), calculated from the start of synthesis to the reformulation of the labeled peptide with PBS.
89 Zr-Df-RGD peptides were achieved with specific activity of 0.11-0.18 mCi/μg (4.07-6.7 MBq/μg).
Competitive Binding Assay with 125 
I-Echistatin Radioligand
The affinity of Df-FK, Df-FK-PEG 3 , Df-[FK] 2 , and Df-[FK] 2 -3PEG 4 to integrin α v β 3 was tested using the human breast carcinoma cell line MDA-MB-435, which is known to express medium level of the integrin [13] . Binding affinities of the Df-RGD conjugates were compared to that of c (RGDfk) (FK) (Fig. 2) (Figs. 3 and 4) . 89 Zr-Df-FK had tumor uptake of 2.3±0.4%ID/g at 1 h post-injection, which remained constant at 2 h (2.0±0.38%ID/g), but was decreased by half at 13 h post-injection (Fig. 3a) . 89 Zr-Df-FK-PEG 3 had slightly lower tumor uptake (1.63±0.35%ID/g at 1 h and 1.57±0.49%ID/g at 2 h post-injection) than 89 Zr-Df-FK (Fig. 3b) . Similar to 89 Zr-Df-FK, the uptake of 89 Zr-Df-FK-PEG 3 in the tumor at 13 h post-injection was also decreased by half (Fig. 3b) Zr-Df-FK-PEG 3 was observed in the liver, which remained high at 13 h post-injection (approximately 15%ID/g, Fig. 3) . Comparison of the kidney uptake between 89 Zr-Df-FK and 89 Zr-Df-FK-PEG 3 showed that 89 Zr-Df-FK had higher renal uptake at all time points (Fig. 3) . 89 Zr-Df-[FK] 2 had high tumor uptake at 0.5 h postinjection (4.51±1.46%ID/g), which remained high at 4 h postinjection (4.44±1.03%ID/g), with a high tumor-to-blood ratio of 16.58±1.54 at 4 h time point (Table 1) . Nevertheless, at 24 h post-injection, the uptake in the tumor was decreased to 2.69±0.43%ID/g (Fig. 4a) . 4 was significantly decreased at 24 h to 2.2±0.26%ID/g (Fig. 4b) , which resulted in a reduced tumor-to-blood ratio (10.82±1.31, Table 1 Zr-Df-RGD peptides (Fig. 4b) .
Representative coronal images of 89 Zr-Df-[FK] 2 -3PEG 4 at different time points post-injection are shown in Fig. 5 . MDA-MB-435 tumors were clearly visualized with good tumor-to-background contrast at 0.5, 1, 2, and 4 h postinjection (Fig. 5) . At 24 h, the uptake in the tumor was decreased, while uptake in the joints and bones was elevated. Therefore, at 24 h post-injection, visualization by PET of the tumor was limited by the low tumor-tobackground ratio (Fig. 5) .
In order to determine the specific binding to integrin α v β 3 in vivo, tumor-bearing mice were co-injected with 89 Zr-Df-[FK] 2 -3PEG 4 and an excess of unlabeled c(RGDfk) (FK) (300 μg per mouse). The uptake in the tumor was decreased by approximately 90% (0.39±0.01%ID/g), confirming the specific binding to integrin α v β 3 (Fig. 5) . The uptake in the liver and kidneys was elevated due to the blocking in the tumor (Fig. 5) .
Biodistribution Studies
Biodistribution of (Table 3) . The results are in good agreement with the PET image quantification (Fig. 4a) . Higher uptake of 89 Zr-Df-[FK] 2 was observed in the liver (17.46±1.85%ID/g) and the kidneys (21.11±3.41% ID/g, Table 3 ). The uptake in the tumor was high (4.04± 0.73%ID/g).
For
89 Zr-Df-[FK] 2 -3PEG 4 , biodistribution in tumor-bearing mice was measured at 4 h post-injection, with and without adding the unlabeled RGD peptide. The uptake in the liver, for 89 Zr-Df-[FK] 2 -3PEG 4 , was significantly lower (6.8 ±0.73%ID/g, Fig. 6 ) than the other three labeled peptides, probably due to higher hydrophilicity of this peptide. The uptake in the tumor was fairly high (3.94± 0.38%ID/g), and this uptake was successfully blocked (reduced to 0.4±0.01%ID/g) when 89 Zr-Df-[FK] 2 -3PEG 4 was co-injected with an excess of unlabeled c(RGDfk) (Fig. 6) . The blocking studies resulted in significant elevation of the uptake in the liver (increased from 6.81± 0.71%ID/g to 18.79±2.21%ID/g), kidneys (increased from 5.93±0.93%ID/g to 16.70±2.74%ID/g), and the spleen (increased from 3.76 ± 0.31%ID/g to 9.50 ± 1.30%ID/g, Fig. 6 ).
Discussion
RGD peptides labeled with various radionuclides were previously investigated for both tumor-targeted imaging and therapy [7, 16, 30, [37] [38] [39] . However, no RGD peptide was previously labeled with 89 Zr. 89 Zr-labeled antibodies showed promising results for immunoPET imaging [40] [41] [42] [43] . 89 Zr has a positron emission decay of 902 KeV, which provides microPET resolution similar to 18 (Fig. 1 ). (Fig. 2) .
Comparison of PET scans and biodistribution data between the four 89 Zr-Df-RGD peptides showed that they all cleared rapidly from the blood (Figs. 3 and 4) . Nevertheless, comparison of 89 Zr-RGD peptides to RGD peptides labeled with other PET isotopes as reported literature [6-8, 13, 33, 34, 44] demonstrate that Cu [44] . This phenomenon might be due to the conjugation to Df, which have reduced clearance rate from the blood.
89 Zr-Df-FK and 89 Zr-Df-FK-PEG 3 had high uptake in metabolic organs, such as liver and kidneys, at all time Results shown are averages of 4-5 mice±SD Results shown are averages of 4-5 mice±SD points ( Fig. 3 and Table 2 ).
89 Zr-Df-FK-PEG 3 had faster clearance through the kidneys than 89 Zr-Df-FK (Fig. 3 ). These differences in the pharmacokinetics were attributed to the addition of PEG functional group, which increases the hydrophilicity of the peptide and therefore accelerates the clearance of the peptide through the kidneys.
89 Zr-Df-FK had slightly higher, but not significant, tumor uptake than 89 Zr-Df-FK-PEG 3 at 1 and 2 h post-injection (Fig. 3) . However, tumor-to-blood ratios were similar for both peptides (8.71±1.81 for 89 Zr-Df-FK and 6.33±1.27 for 89 Zr-Df-FK-PEG 3 at 2 h post-injection). The ability to image later time points because of the longer half-life of 89 Zr was of little advantage as the tumor uptake was decreased at later time points and excretion tissues increased. Even the slower clearance of the dimeric ligands could be observed by 4 h.
Out of the four peptides, the dimeric peptides gave better tumor uptake and tumor-to-blood ratio (Fig. 4 and Table 1 ) than the monomeric analogs. This may be explained by the bivalent binding of the dimer to integrins on the cell surface, which significantly reduces the dissociation of the tracer from its target [44] . Between the two dimers, 89 Zr-Df-[FK] 2 -3PEG 4 had slightly better imaging figure of merit, probably due to the longer spacer connecting the two RGD moieties, that confers less limitation on the distance between integrins on the cell surface [44] . The presence of three short PEG groups is also expected to have an effect on the tumor targeting and in vivo kinetics. Accordingly, 89 Zr-Df-[FK] 2 -3PEG 4 had the best overall tumor-to-background contrast and serves as an appropriate integrin imaging agent. Blocking studies by co-injection of 89 Zr-Df-[FK] 2 -3PEG 4 and unlabeled c(RGDfk) showed a significant decrease in the tumor uptake, suggesting a specific binding of this tracer to integrin α v β 3 . In this same experiment, blocking was detected in other organs, such as stomach, pancreas, intestine, heart, and muscle, which suggests that the binding of 89 Zr-Df-[FK] 2 -3PEG 4 to these organs is partially integrin α v β 3 mediated.
Biodistribution studies for all four peptides showed unexpectedly high uptake in the spleen which does not express high level of integrin α v β 3 . This phenomenon has not been reported in other radiolabeled RGD peptides. Moreover, in blocking studies the accumulation in the spleen, liver, and kidneys was increased (Fig. 6 ), suggesting that this accumulation is not integrin specific but can be related to 89 Zr. Another hypothesis is that increasing amounts of unlabeled peptide (≥300 μg) which had to be cleared could have been redirected to clearance routes other than the kidneys, such as uptake by hepatocytes and macrophages.
An elevated uptake was also detected in the bones and joints 24 h post-injection (Figs. 4 and 5, Table 2 ), which implies the decomplexation of 89 Zr from the Df chelator [43] . Although 89 Zr has favorable positron emission decay compared to other radiometals, elevated uptake in the bone and the decreased uptake in the tumor over time result in reduced tumor visualization by microPET scans.
Other chelators for zirconium such as desferrioxamine B (DFO), derivatives of DFO using amino reactive linkers and thiol reactive linkers [41, 43] , and diethylenetriaminepentaacetic acid (DTPA) [45] have been evaluated; however, decomplexation of the zirconium and uptake in the bone was evident in all of them at 24 h or longer time points post-injection. The need for a more stable chelator that does not undergo decomplexation in vivo has not been met. 89 Zr and its accumulation in the bone, along with a decrease in the tumor uptake due to fast clearance of peptides, suggest that labeling RGD peptides with long half-life isotope such as 89 Zr is not favorable. Further optimization of the chelator structures for more stable 89 Zr complexation is needed. 
Conclusions
